exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087768 RNA Name: hsa-miR-140-5p RNA Type: miRNA Chromosome: chr16 Starnd: + Coordinate: Start Site(bp): 69933103 End Site(bp): 69933124 External Links: hsa-miR-140-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ARIH1 chr15 72474330 72602987 + BTBD7 chr14 93237550 93333092 - C15orf41 chr15 36579626 36810248 + CLPTM1 chr19 44954585 44993341 + COL4A2 chr13 110305812 110513209 + ITPRIPL2 chr16 19113932 19121629 + NME4 chr16 396725 410367 + POLR3G chr5 90471748 90514557 + SCRN1 chr7 29920104 29990289 - SLC6A6 chr3 14402576 14489349 + SRP14 chr15 40035690 40039181 - TMEM181 chr6 158536436 158635428 + TNRC6B chr22 40044817 40335808 + TRIO chr5 14143342 14532128 + ZNF800 chr7 127346790 127431924 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000712 chr16 68208276 68225678 + hsa_circ_0001699 chr7 40027197 40041630 + hsa_circ_0001472 chr5 36953719 36976504 + hsa_circ_0000032 chr1 25666964 25669564 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AL162258.1 chr1 153626332 153634340 - DHRS4-AS1 chr14 23938219 24052555 - H19 chr11 1995176 2001470 - KCNQ1OT1 chr11 2608328 2699994 - MALAT1 chr11 65497688 65506516 + NEAT1 chr11 65422774 65445540 + SNHG1 chr11 62851984 62855953 - SNHG16 chr17 76557764 76565348 + SNHG20 chr17 77086716 77099902 + TDRKH-AS1 chr1 151790804 151794402 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.